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Aim of this work was to investigate a possible correlation between the frequency of JCV-specific T-cells and PML 
occurrence in HIV-infected subjects and in liver transplant recipients. 
A significant decrease of JCV-specific T-cells was observed in HIV-PML subjects, highlighting a close relation be-
tween JCV-specific T-cell immune impairment and PML occurrence in HIV-subjects. Interestingly, liver-transplant 
recipients (LTR) showed a low frequency of JCV-specific T-cells, similar to HIV-PML subjects. Nevertheless, none 
of the enrolled LTR developed PML, suggesting the existence of different immunological mechanisms involved in 
the maintenance of a protective immune response in LTR. 
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Progressive multifocal leukoencephalopathy 
(PML) is a rare often fatal demyelinating dis-
ease of the central nervous system caused by 
the reactivation of the human polyomavirus 
JC (JCV) (Ferenczy et al., 2012). Although as-
ymptomatic JCV primary infection occurs in 
the large majority of the general population, 
reactivation resulting in PML is observed main-
ly in immunosuppressed individuals, including 
HIV-infected persons, cancer patients, organ 
transplant recipients, and patients undergoing 
lymphocyte-targeted drug treatment for auto-
immune diseases (Ferenczy et al., 2012). 
In HIV infection, the PML-attributable 1-year 
mortality rate is greater than 50% in AIDS pa-
tients (Antinori et al., 2003), with 80% of sur-
vivors showing persistent severe neurological 
impairment. Nevertheless, despite the lack of 
specific treatment, the immune reconstitution 
induced by combined antiretroviral therapy 
(cART) has significantly improved survival in 
AIDS patients (Antinori et al., 2003). In the HIV 
population, JCV-specific T-cells have been re-
ported to play a major role in containing JCV 
reactivation, and were associated with an im-
proved PML clinical outcome (Du Pasquier 
et al., 2001). Specifically, the early detection 
of JCV-specific CTL in HIV+ patients had an 
87% predictive value for subsequent control 
of PML (Du Pasquier et al., 2004). In contrast, 
PML non-survivors had selectively impaired 
JCV-specific T-cell responses (Khanna et al., 
2009). 
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Organ transplant recipients represent a risk 
group for developing PML due to the immuno-
suppressive regimens. In this clinical setting, 
the survival rate remains extremely poor and 
the only available treatment option is reduc-
ing and/or terminating the immunosuppressive 
regimen (Mateen et al., 2011; Shitrit et al., 2005; 
Verhelst et al., 2011). 
The identification of a prognostic bio-marker 
able to identify patients with an increased risk 
for developing PML would represent a useful 
tool in the clinical management of immuno-
suppressed patients. Unfortunately, effective 
prognostic markers are still lacking. Active JCV 
replication in urine or plasma does not cor-
relate with an increased risk of developing PML 
(Koralnik et al., 1999). Notably, JCV-specific 
T-cells have been shown to play a major role in 
containing JCV reactivation, and have been pro-
posed as a prognostic marker for HIV patients 
at risk of PML (Khanna et al., 2009). No data are 
available on the possible predictive value of this 
marker in liver transplant recipients.
Aim of this work was to investigate a possible 
correlation between the frequency of JCV-spe-
cific T-cells and PML occurrence in two dif-
ferent immuno-compromised groups: HIV-in-
fected subjects and liver transplant recipients 
(LTR). 
Specifically, we enrolled:
1) PML-free HIV-infected patients (HIV-PML-
free, n=16);
2) HIV-infected patients with a PML diagnosis 
(HIV-PML, n=4);
3) LTR recipients (n=11). Healthy donors (HD, 
n=10) were enrolled as controls.
Clinical features of enrolled patients are re-
ported in Table 1A. All HIV patients were under 
cART treatment, and peripheral blood of HIV-
PML subjects was obtained within 3 days from 
diagnosis. All LTR patients are under immu-
nosuppressive regimens, and underwent liver 
transplant for HCV-related (n=7), HBV-related 
(n=2), and alcoholic-related (n=2) pathologies. 
Laboratory tests were performed using anony-
mised residual samples obtained for diagnostic 
purpose. The presence of JCV-DNA in the ce-
rebrospinal fluid together with evidence of de-
myelinating white matter lesions at magnetic 
resonance imaging in patients with compatible 
clinical features were considered diagnostic for 
PML (Berger et al., 2013). JCV-DNA was quan-
tified by real time PCR (Koralnik et al., 1999).
As described in Table 1A, although not reaching 
statistical significance, the CD4 T cell number 
was lower in HIV-PML subjects compared to 
HIV-PMLfree (HIV-PML: 245±179 vs. HIV-PM-
Lfree: 545±121, p>0.05). Moreover, all HIV-
TABLE 1 - Patients
1A - Enrolled subjects
Patients N Gender
(M/F)
Mean Age 
(years)
Mean
CD4/mmc
Plasma HIV
Viral load (VL) (cp/ml)
Treatment
HD 10 5/5 54.7 n.t. n.t. None
HIV-PMLfree 16 13/3 49.4 545 ± 121 <40 (11 patients)
40<VL<1000 (3 patients)
VL >10000 (2 patients)
cART
HIV-PML 4 4/0 51.7 245± 179 <40 (2 patients)
40<VL<60 (2 patients)
cART
LTR 11 9/2 55.3 n.t. n.t. Tacrolimus (n=10)
Everolimus (n=1)
1B - Immunological and virological features of HIV-PML subjects
HIV-PML
patients
CD4
(CD4/mmc)
CSF
JCV-DNA 
(cp/ml)
CSF
HIV-RNA
(cp/ml)
JCV-specific
T-cells
(SFCs/106PBMC)
Outcome at 2 years
#1 115 2144 Undetected 68 survivor
#2 334 392 54 40 nonsurvivor
#3 77 150 Undetected 0 nonsurvivor
#4 454 249 Undetected 83 survivor
n.t.: not tested; CSF: cerebrospinal fluid.
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PML patients showed undetected/low HIV plas-
ma viral load, suggesting that PML occurrence 
was not associated with high HIV replication. 
Finally, HIV-RNA as well as JCV-DNA was test-
ed in CSF (Table 1B). HIV-RNA was detected at 
low copies only in 1/4 HIV-PML and JCV-DNA 
ranged between 150-2144 cp/ml. HIV-PML sur-
vival outcome was defined at the end of 2 years 
follow-up. Neither CD4 T cell number nor HIV-
RNA (either in plasma and in CSF), nor JCV-
DNA viral load in CSF were associated with the 
outcome of PML (survivors/non-survivors). 
JCV-specific T-cell immunity was analysed by 
ELISpot assay. Briefly, peripheral blood mono-
nuclear cells (PBMCs) were isolated from 
whole blood and stimulated for 20 hours with 
peptides from VP1 and LT1 JCV proteins in the 
presence of 1mg/ml aCD28 and aCD49d (Bec-
ton Dickinson, Mountain View, CA, USA). PHA 
stimulation was used as a positive control to 
assess the functionality of immune cells, and 
all enrolled patients showed a good response 
(data not shown). Spontaneous (background) 
cytokine production was assessed by incubat-
ing PBMC with aCD28 and aCD49d. Results 
were expressed as spot-forming cells (SFC)/106 
PBMCs in stimulated cultures, after having 
subtracted background. Statistical analysis was 
performed using non-parametric Mann-Whit-
ney test. Differences were considered signifi-
cant when the p-value was less than 0.05. Sta-
tistical evaluations were performed by Graph-
Pad Prism software (GraphPad).
As shown in Figure 1, a similar frequency of 
JCV-specific T-cells was detected in the pe-
ripheral blood of HD and HIV-PMLfree sub-
jects [HD: 100 SFC/106 PBMC (IQR: 71-158) 
vs HIV-PMLfree: 136 SFC/106PBMC (IQR: 66-
209)]. By contrast, HIV-PML subjects showed 
a significant decrease in the frequency of 
JCV-specific T-cells when compared to both HD 
[HIV-PML: 54 SFC/106PBMC(IQR: 20-75.5) vs 
HD: 100 SFC/106PBMC(IQR: 71-158), p<0.05] 
and to HIV-PMLfree patients [HIV-PML: 54 SF-
C/106PBMC(IQR: 20-75.5) vs HIV-PMLfree: 136 
SFC/106PBMC(IQR: 66-209), p<0.05], suggest-
ing a close relation between JCV-specific T-cell 
immune impairment and PML occurrence in 
HIV-infected patients. Moreover, a positive 
JCV-specific T-cell response was found in 2/2 
(100%) of HIV-PML survivors and in 1/2 (50%) 
of HIV-PML non-survivors (Table 1B). These 
data confirm published results, highlighting 
the major role of JCV-specific T cells in disease 
containment and survival during PML in an 
HIV clinical setting (Du Pasquier et al., 2001; 
Du Pasquier et al., 2004; Khanna et al., 2009). 
Indeed, this factor has been proposed as a prog-
FIGURE 1 - JCV-specific T cell fre-
quency. JCV-specific T-cells are an-
alysed in HD (n=8), HIV-PMLfree 
(n=12), HIV-PML (n=4) and LTR 
(n=11) by ELISpot assay. Results are 
expressed as SCFs/106PBMC.
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nostic marker for HIV patients at risk of PML 
(Khanna et al., 2009).
In order to verify whether JCV-specific T-cell 
immunity may be used as a marker associated 
with PML occurrence also in another highly im-
munosuppressed clinical settings, LTR were en-
rolled. LTR showed a low frequency of JCV-spe-
cific T-cells, similar to HIV-PML subjects [LTR: 
33 SFC/106PBMC (IQR: 0-109.5) vs. HIV-PML: 
54 SFC/106PBMC (IQR: 20-75.5)]. Interestingly, 
none of the enrolled LTR developed PML, sug-
gesting that unlike HIV-infected subjects, a low 
frequency of JCV-specific T-cells was not asso-
ciated with the onset of PML in LTR. Despite 
the small sample size and the lack of an LTR-
PML group, our results may suggest different 
immunological mechanisms able to drive a pro-
tective immune response in HIV and LTR. 
Several immunological mechanisms can be in-
voked to explain the different behaviour of HIV 
and LTR patients, as polyfunctional properties 
and/or exhaustion/regulation/trafficking mark-
er expression. In this study, JCV-specific T-cells 
were identified as cells able to produce IFN-g 
after JCV specific stimulation. Nevertheless, it 
is well-known that virus-specific T-cells exert 
their antiviral functions by producing a large 
panel of cytokines/chemokines and also by me-
diating a direct cytotoxic activity. Indeed, it is 
also well-accepted that a polyfunctional pro-
file of T-cells rather than a simple function is 
associated with protection in viral infections 
(Seder et al., 2008). Moreover, the expression of 
exhaustion/regulation markers may be involved 
in regulating the cytokine profile and thus mod-
ulating the protective efficacy (Tan et al., 2012). 
Thus, we may speculate that in LTR, polyfunc-
tional/IFN-g negative JCV-specific T-cells were 
able to maintain a sufficient level of protective 
immunity to avoid JCV reactivation. Final-
ly, L-selectin expression on CD4 T cell surface 
has been proposed as a marker associated with 
PML in HIV patients (Schneider-Hohendorf et 
al., 2014). 
New studies are necessary to verify the hypoth-
esis that other T cell functions (e.g., perforin ex-
pression, TNF-a, IL-2 production, etc) as well 
as the expression of biomarkers may be used to 
evaluate LTR at risk of PML. Although repre-
senting an extremely rare population (Verhelst 
et al., 2011), work is in progress on the enrol-
ment of LTR-PML subjects. This may represent 
a critical step to dissect immunological protec-
tive mechanisms in the clinical transplant set-
ting. Overall, this study showed that the quan-
tification of JCV-specific T-cells only by IFN-g 
production was not a useful marker to identify 
LTR patients with PML.
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